Recent FDA approval of exa-cel & lovo-cel for patients with SCD

Akshat Jain, MD, MPH, FRCP, Loma Linda University, San Bernadino, CA, shares insights into the exciting recent FDA approval of two gene therapies, lovotibeglogene autotemcel (lovo-cel) and exagamglogene autotemcel (exa-cel), for patients with sickle cell disease (SCD). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.